Current Topic

STRIVING FOR
TRANSFORMATIONAL VALUE :

Are we ready for radical change?
Basel : September 2018
New Jersey : April 2019

Previous Events:

PATIENTCENTRICITY :
defining our role

REAL WORLD EVIDENCE :
the new standard of proof

PERSONALISED MEDICINE :
moving from promise to practice

THE PATIENT EXPERIENCE IN CONTEXT : understanding its impact on
pharmaceutical strategies of the future

MARKET ACCESS : aligning regulatory
and commercial strategies

25th October 2017  |  San Francisco, USA

Key takeaways

  • If the ultimate goal is to maximize therapeutic outcome and positive experience for the patient, what responsibilities should we embrace in order to make a constructive contribution?
  • Everybody is claiming patientcentricity: What should our industry aspire to achieve?

Speakers

John H. Powers, MD FACP FIDSA  – Professor of Clinical Medicine at George Washington University School of Medicine

Andreas M. Pleil, Ph.D – Senior Director, Team Lead, Outcomes & Evidence Hematology Global Health & Value, Pfizer Inc.

Lulu McCartin, MBA – Business Insights & Analytics; Senior Executive, formerly Senior Director of Insights, Celgene

Overview

16 Clients attended
Amgen, Corcept Therapeutics, Eiger BioPharmaceuticals, Five Prime Therapeutics, ics Genentech, Jazz Pharmaceuticals, Revance Therapeutics, Theravance , Biophama, Ultragenyx